Recording intelligenceAI-generated brief · check the source for context

Bacterial Vaginosis and T-Cell Dysfunction

1:14:43 recording · AUTO · 2 speakers

Listen to the original

Listen to the episode
Executive Summary AI
  • Steph Langel presents "Bacterial Vaginosis Associates with Dysfunctional T-Cells and Altered Soluble Immune Factors in the Cervical Vaginal Tract", first-authored by Finn McLean, with Jennifer Lund and Jaram Lingapa contributing equally as senior authors from Fred Hutch, the University of Washington and Nairobi.2:41
  • The Kinga cohort covered 204 Kenyan women, sampled by vaginal swab, ectocervical biopsy, PBMCs, cervical vaginal fluid and serum, and read out by flow cytometry, immunofluorescent imaging and Luminex cytokine profiling.8:50
  • Women with BV showed higher CCR5 and HLA frequencies, raised CD39 and CD101 markers of exhaustion, fewer TCF1-positive stem-like CD4 cells and CD8 cells with reduced granzyme B, a locally suppressed state in a condition that hits about one in four women and recurs in one in two after antibiotics.12:12
  • Cindy Leifer then takes "Somatic hypermutation generates antibody specificities beyond the primary repertoire", first author Tang Zhu and last author Dwayne Westman at Harvard, published in Immunity over the summer, which challenges the textbook idea that hypermutation only refines an existing specificity.20:46
  • Using RAG-knockout mice whose B cells carry only an HA-specific receptor, repeated immunisation with ovalbumin, PCC or CGG drove those bystander cells into germinal centres with up to 20, 25 mutations and yielded cloned antibodies binding ova in the nanomolar range.47:42

Brief overview

Two immunologists review evidence that bacterial vaginosis exhausts cervical T cells and that somatic hypermutation births new specificities.

  1. The healthy vagina wants a monoculture, not diversityLactobacillus crispatus dominance keeps the pH low; polymicrobial state types bring inflammation and BV.
  2. BV leaves cervical T cells exhausted, not absentCD39 and CD101 up, TCF1 stem-like cells down, granzyme B reduced, with more CCR5 for HIV entry.
  3. Hypermutation can birth specificities the repertoire never hadHA-only B cells gained nanomolar binding to ova, PCC and CGG they could not bind before.

Questions this recording answers

10 questions, each answered where it is said
Why does bacterial vaginosis make HIV infection more likely?

HIV infects CD4 T cells using two co-receptors, CCR5 and CXCR4, so how much of those receptors a cell carries sets its susceptibility. Women with BV had higher frequencies of CCR5 and HLA positive cells, plus suppressed killer cells: more infectable targets and fewer cells able to kill infected ones.

Answered around 9:46
What did the study find on the T cells of women with BV?

Beyond CCR5, two markers were raised on their CD4 T cells: CD39 and CD101, both markers of metabolic stress, dysfunction, inhibition and exhaustion, in cervix and vaginal tissue. They also found fewer TCF1 positive CD4 T cells, a marker of stemness, so fewer progenitors left to differentiate.

Answered around 12:07
What does a healthy vaginal microbiome look like?

Unlike the gut, where diversity is what counts as healthy, the vaginal canal wants close to a monoculture: majority lactobacillus, particularly crispatus, which thrives by producing chemicals that keep the pH very low. Polymicrobial states with Gardnerella or other lactobacillus such as iners are associated with dysbiosis and inflammation.

Answered around 4:13
Is bacterial vaginosis treatable, and does it come back?

It is treatable by antibiotics, but of the women treated the recurrence rate is one in two, so 50 percent have reoccurring BV. Roughly one in four women get it at some point, and it is linked to increased STIs, preterm birth and preeclampsia. Trials add lactobacillus crispatus as a probiotic.

Answered around 6:47
How do clinicians decide whether someone has BV?

The Nugent score is the gold standard in clinical settings. It is based on the relative presence of three main bacterial types: lactobacillus, Gardnerella and Mobiluncus. Determining how much of each is present gives the score, and a higher Nugent score means BV while a lower score means you do not.

Answered around 5:11
What samples and methods did the Kenyan cohort study use?

A cohort of 204 Kenyan women gave many sample types: vaginal tract samples, ectocervical biopsies, PBMCs, cervical vaginal fluid and serum. The team ran flow cytometry, immunofluorescent imaging and Luminex cytokine and chemokine profiling, comparing women with and without BV. The groups were at Fred Hutch, University of Washington and Nairobi.

Answered around 8:50
What was somatic hypermutation thought to do to antibodies?

The textbook definition is refinement of specificity: something that already binds is mutated so that it binds better, like putty fitting a groove even more closely. The enzyme behind it is activation-induced cytidine deaminase, which deaminates cytidines and changes the sequence at the antibody variable region.

Answered around 26:06
How did they test whether B cells can create brand new specificities?

They used mice whose B cells carry one clonal B cell receptor on a RAG knockout background, so no VDJ recombination: one antibody only, specific for influenza hemagglutinin and nothing else. Congenic markers and distinguishable antibody types let them track which cells and which antibodies came from that clonal population.

Answered around 31:54
What happened when those hemagglutinin B cells met an unrelated antigen?

Mixed with B cell deficient muMT bone marrow, all the mice made detectable serum responses: OVA specific, PC specific and CGG specific. The HA antibodies had mutated and gained specificity for those antigens. Cloned monoclonals confirmed it, with the HA antibody binding ova in the nanomolar range.

Answered around 46:03
Does blocking CTLA-4 make this happen more often?

In the first experiment there was almost no serum reactivity from the clonal cells, only germinal center B cells. Blocking the inhibitory signals on T cells produced some serum reactivity to PCC and a lot more to CGG, still none to ova, plus more germinal center B cells and more unique mutations.

Answered around 58:37
Key Quote

“So the local immune dysregulation, it's not just systemic in blood.”

— Steph Langel, Bacterial Vaginosis and T-Cell Dysfunction, at 14:38▶ listen at 14:38
Key Quote

“I mean, they're just undergoing Darwinian evolution all the time in our body.”

— Cindy Leifer, Bacterial Vaginosis and T-Cell Dysfunction, at 20:30▶ listen at 20:30
Key Quote

“So really you can birth these new antibodies from an existing antibody that has completely different specificity.”

— Cindy Leifer, Bacterial Vaginosis and T-Cell Dysfunction, at 50:40▶ listen at 50:40
Key Quote

“And this would provide an opportunity to make specificities to practically anything.”

— Cindy Leifer, Bacterial Vaginosis and T-Cell Dysfunction, at 1:05:28▶ listen at 1:05:28

Cite this

“Bacterial Vaginosis and T-Cell Dysfunction.” https://traffic.libsyn.com/secure/immune/Immune097.mp3. Transcript summary by WhipScribe, https://whipscribe.com/transcript-pages/bacterial-vaginosis-and-t-cell-dysfunction.html.

Report this page
What is wrong with this page?